Roche, BMS Hope to Improve Outcomes in BRAF-Mutated Melanoma Patients with Dual Treatment Regimen | GenomeWeb

Originally published June 6.

By Turna Ray

CHICAGO — By exploring a treatment strategy that involves Roche/Plexxikon's investigational pharmacogenomically targeted drug vemurafenib and Bristol-Myers Squibb's newly approved melanoma treatment Yervoy, two large drug developers are hoping to further improve outcomes for a genomically defined patient population.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.